Proteins and Peptides
20 September 2018
ERYTECH Announces Enrollment of First Patients in Phase 3 Clinical Trial Evaluating Eryaspase for the Treatment of Second Line Pancreatic Cancer19 September 2018
BioAegis Therapeutics Enrolls First Patients in Phase 1b/2a Community-Acquired Pneumonia Study and Raises $4 MM in Equity Round18 September 2018
Zealand Pharma achieves primary and key secondary endpoints in pivotal Phase 3 trial with dasiglucagon for severe hypoglycemia17 September 2018
Oramed Receives FDA Clearance for IND Application for Its Oral GLP-1 Analog Capsule17 September 2018
Aeglea BioTherapeutics Announces Oral Presentation of Preclinical Data on New Pipeline Therapeutic for Cystinuria at 2018 American Society of Nephrology15 September 2018
Allergan Announces Results of Higher Dose BOTOX® Cosmetic (onabotulinumtoxinA) for the Treatment of Moderate to Severe Glabellar Lines12 September 2018
Shire granted EU marketing authorization for Veyvondi® [vonicog alfa, recombinant von willebrand factor] for adults with von Willebrand disease10 September 2018
Alkermes Initiates Clinical Evaluation of Novel Immuno-Oncology Drug Candidate ALKS 4230 in Combination With PD-1 Inhibitor Pembrolizumab10 September 2018
Amicus Therapeutics Announces Regulatory and Clinical Updates for AT-GAA in Pompe Disease6 September 2018
PvP Biologics Announces First-in-Human Clinical Trials for a Novel Therapeutic for Celiac Disease6 September 2018
ContraFect Completes Enrollment in Phase 2 Clinical Trial Evaluating CF-301 (exebacase) in Patients with Staphylococcus Aureus Bacteremia5 September 2018
Thrombolytic Science Initiates Phase 2 Clinical Trial of its Novel Treatment Regimen for Ischemic Stroke30 August 2018
Bayer Receives FDA Approval for Jivi®, New Hemophilia A Treatment With Step-Wise Prophylaxis Dosing Regimen30 August 2018
European Commission approves new easy-to-use, once-weekly Bydureon BCise device for patients with type-2 diabetes28 August 2018
Ultragenyx Announces Approval of Mepsevii™ (vestronidase alfa) in Europe for the Treatment of Mucopolysaccharidosis VII10 August 2018
First patient dosed in phase 1/2 study evaluating SOBI003 for treatment of mucopolysaccharidosis type IIIA (MPS IIIA)9 August 2018
I-Mab’s Announces China Clinical Trial Approval of Long-acting hGLP-1 to Treat Type 2 Diabetes6 August 2018
amcure Announces First Patient Dosed with AMC303 in Phase Ib Extension Cohort Based on Positive Safety Results5 August 2018
OPKO Health Completes Enrollment in Global Phase 3 Study of Somatrogon (hGH-CTP) in Growth Hormone Deficient Children2 August 2018
Evolus Announces Early Resubmission to the FDA of its Biologics License Application for DWP-450News Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe